XML 71 R54.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment and Geographical Data (Tables)
 12 Months Ended
Dec. 29, 2017
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Business Segment
Selected information by business segment is as follows:

Fiscal Year Ended
 
Three Months Ended

December 29, 2017
 
September 30, 2016
 
September 25, 2015
 
December 30, 2016
Net sales:
 
 
 
 
 
 
 
Specialty Brands
$
2,325.3

 
$
2,300.6

 
$
1,622.8

 
$
603.1

Specialty Generics
839.5

 
1,025.2

 
1,251.6

 
212.9

Net sales of operating segments (1)
3,164.8

 
3,325.8

 
2,874.4

 
816.0

Other (2)
56.8

 
55.0

 
48.7

 
13.9

Net sales
$
3,221.6

 
$
3,380.8

 
$
2,923.1

 
$
829.9

Operating income:
 
 
 
 
 
 
 
Specialty Brands
$
1,155.2

 
$
1,166.2

 
$
637.6

 
$
317.2

Specialty Generics
231.5

 
376.1

 
594.4

 
52.7

Segment operating income
1,386.7

 
1,542.3

 
1,232.0

 
369.9

Unallocated amounts:
 
 
 
 
 
 
 
Corporate and allocated expenses (3)          
(172.0
)
 
(169.8
)
 
(282.6
)
 
(181.4
)
Intangible asset amortization
(694.5
)
 
(700.1
)
 
(550.3
)
 
(175.7
)
Restructuring and related charges, net (4)
(36.4
)
 
(38.2
)
 
(45.3
)
 
(5.3
)
Non-restructuring impairments
(63.7
)
 
(16.9
)
 
—

 
(214.3
)
Operating income
$
420.1

 
$
617.3

 
$
353.8

 
$
(206.8
)
 
 
 
 
 
 
 
 
Depreciation and amortization (5):
 
 
 
 
 
 
 
Specialty Brands
$
708.2

 
$
716.6

 
$
559.5

 
$
178.4

Specialty Generics
100.1

 
96.8

 
81.6

 
24.8

 
$
808.3

 
$
813.4

 
$
641.1

 
$
203.2

(1)
Amounts represent sales to external customers. There were no intersegment sales.
(2)
Represents net sales from an ongoing, post-divestiture supply agreement with the acquirer of the CMDS business. Amounts for periods prior to the divestiture represent the reclassification of intercompany sales to third-party sales to conform with the expected presentation of the ongoing supply agreement.
(3)
Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
(4)
Includes restructuring-related accelerated depreciation.
(5)
Depreciation for certain shared facilities is allocated based on occupancy percentage.

 [1],[2],[3],[4],[5]
Schedule of Net Sales from External Customers by Products
Net sales by product family within the Company's segments are as follows:
 
Fiscal Year Ended
 
Three Months Ended
 
December 29, 2017
 
September 30, 2016
 
September 25, 2015
 
December 30, 2016
H.P. Acthar Gel
$
1,195.1

 
$
1,160.4

 
$
1,037.3

 
$
325.4

Inomax
505.2

 
474.3

 
185.2

 
118.3

Ofirmev
302.5

 
284.3

 
263.0

 
72.5

Therakos
214.9

 
207.6

 
—

 
47.4

Hemostasis products
55.1

 
42.5

 
—

 
13.4

Other
52.5

 
131.5

 
137.3

 
26.1

Specialty Brands
2,325.3

 
2,300.6

 
1,622.8

 
603.1

 
 
 
 
 
 
 
 
Hydrocodone (API) and hydrocodone-containing tablets
85.3

 
146.5

 
167.2

 
23.2

Oxycodone (API) and oxycodone-containing tablets
78.8

 
126.2

 
154.6

 
24.3

Methylphenidate ER
71.7

 
103.5

 
136.5

 
22.0

Other controlled substances
409.6

 
468.1

 
572.2

 
104.9

Other
194.1

 
180.9

 
221.1

 
38.5

Specialty Generics
839.5

 
1,025.2

 
1,251.6

 
212.9

 
 
 
 
 
 
 
 
Other (1)
56.8

 
55.0

 
48.7

 
13.9

Net sales
$
3,221.6

 
$
3,380.8

 
$
2,923.1

 
$
829.9

(1)
Represents net sales from an ongoing, post-divestiture supply agreement with the acquirer of the CMDS business. Amounts for periods prior to the divestiture represent the reclassification of intercompany sales to third-party sales to conform with the expected presentation of the ongoing supply agreement.

 [6]
Schedule of Net Sales and Long-Lived Assets by Geographical Area
Selected information by geographic area excluding assets held for sale is as follows:
 
Fiscal Year Ended
 
Three Months Ended
 
December 29, 2017
 
September 30, 2016
 
September 25, 2015
 
December 30, 2016
Net sales (1):
 
 
 
 
 
 
 
U.S.
$
2,899.0

 
$
3,095.4

 
$
2,647.0

 
$
763.7

Europe, Middle East and Africa
242.3

 
211.8

 
159.0

 
52.8

Other
80.3

 
73.6

 
117.1

 
13.4

 
$
3,221.6

 
$
3,380.8

 
$
2,923.1

 
$
829.9

 
 
 
 
 
 
 
 
 
Fiscal Year Ended
 
 
 
 
Long-lived assets (2):
December 29, 2017
 
December 30, 2016
 
 
 
 
U.S.
$
788.5

 
$
759.1

 
 
 
 
Europe, Middle East and Africa (3)
127.0

 
82.9

 
 
 
 
Other
63.5

 
51.5

 
 
 
 
 
$
979.0

 
$
893.5

 
 
 
 
(1)
Net sales are attributed to regions based on the location of the entity that records the transaction, none of which relate to the country of Ireland.
(2)
Long-lived assets are primarily composed of property, plant and equipment, net.
(3)
Includes long-lived assets located in Ireland of $126.0 million and $80.9 million as of December 29, 2017 and December 30, 2016, respectively.

 [7],[8],[9]
[1] Amounts represent sales to external customers. There were no intersegment sales.
[2] Depreciation for certain shared facilities is allocated based on occupancy percentage.
[3] Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
[4] Includes restructuring-related accelerated depreciation.
[5] Represents net sales from an ongoing, post-divestiture supply agreement with the acquirer of the CMDS business. Amounts for periods prior to the divestiture represent the reclassification of intercompany sales to third-party sales to conform with the expected presentation of the ongoing supply agreement.
[6] Represents net sales from an ongoing, post-divestiture supply agreement with the acquirer of the CMDS business. Amounts for periods prior to the divestiture represent the reclassification of intercompany sales to third-party sales to conform with the expected presentation of the ongoing supply agreement.
[7] Includes long-lived assets located in Ireland of $126.0 million and $80.9 million
[8] Long-lived assets are primarily composed of property, plant and equipment, net.
[9] Net sales are attributed to regions based on the location of the entity that records the transaction, none of which relate to the country of Ireland.